NIKKEI 225
39,586.49 +3.41 (+0.01%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
81.92 +0.38 (+0.47%) GOLD FUTURES
2,336.10 -3.50 (-0.15%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
50,037.20 +2,030.03 (+4.23%)
DYN Jan 2026 30.000 call
| Previous close | 12.79 |
| Open | N/A |
| Bid | 11.50 |
| Ask | 15.90 |
| Strike | 30.00 |
| Expiry date | 2026-01-16 |
| Day's range | 12.79 - 12.79 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireDyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New D
- GlobeNewswire
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystroph
- GlobeNewswire
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne’s w
